Company intelligence / Profile preview

Nemucore Medical Innovations

Wellesley, Massachusetts, United States

Ownership: Private
Development stage: Other

Overview

Nemucore's lead program NMI-900, an Aurora kinase inhibitor for AML, has shown promise in preclinical studies with high Aurora B kinase correlation to AML and positive signals in animal models.[2] The company pairs this therapeutic with a companion diagnostic using RNA measurement (rather than DNA) to identify patients who will respond to treatment.[6]

Therapeutic areas: OncologyHematology
Modalities: Small moleculeNanoparticle
Industry: Biotech

Drug pipeline

2 assets

NMI-900

1 more asset in the full pipeline.

Request access →

Partnerships

Medical Prognosis Institute (MPI) - partnership for companion diagnostic development using MPI's Drug Response Predictor platform

Beyond the preview

Go deeper on Nemucore Medical Innovations.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Nemucore Medical Innovations.

Explore the full profile